250 related articles for article (PubMed ID: 19307220)
21. Low Density Lipoprotein Receptor-Related Protein-1 (LRP1) Is Involved in the Uptake of
Schöttelndreier D; Langejürgen A; Lindner R; Genth H
Front Cell Infect Microbiol; 2020; 10():565465. PubMed ID: 33194803
[TBL] [Abstract][Full Text] [Related]
22. Structural basis for antibody recognition in the receptor-binding domains of toxins A and B from Clostridium difficile.
Murase T; Eugenio L; Schorr M; Hussack G; Tanha J; Kitova EN; Klassen JS; Ng KK
J Biol Chem; 2014 Jan; 289(4):2331-43. PubMed ID: 24311789
[TBL] [Abstract][Full Text] [Related]
23. Clostridioides difficile Toxin A Remodels Membranes and Mediates DNA Entry Into Cells to Activate Toll-Like Receptor 9 Signaling.
Chen X; Yang X; de Anda J; Huang J; Li D; Xu H; Shields KS; Džunková M; Hansen J; Patel IJ; Yee EU; Golenbock DT; Grant MA; Wong GCL; Kelly CP
Gastroenterology; 2020 Dec; 159(6):2181-2192.e1. PubMed ID: 32841647
[TBL] [Abstract][Full Text] [Related]
24. Sulfated glycosaminoglycans and low-density lipoprotein receptor contribute to Clostridium difficile toxin A entry into cells.
Tao L; Tian S; Zhang J; Liu Z; Robinson-McCarthy L; Miyashita SI; Breault DT; Gerhard R; Oottamasathien S; Whelan SPJ; Dong M
Nat Microbiol; 2019 Oct; 4(10):1760-1769. PubMed ID: 31160825
[TBL] [Abstract][Full Text] [Related]
25. Development of a non-radiolabeled glucosyltransferase activity assay for C. difficile toxin A and B using ultra performance liquid chromatography.
Loughney JW; Lancaster C; Price CE; Hoang VM; Ha S; Rustandi RR
J Chromatogr A; 2017 May; 1498():169-175. PubMed ID: 28238427
[TBL] [Abstract][Full Text] [Related]
26. A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile.
Donald RGK; Flint M; Kalyan N; Johnson E; Witko SE; Kotash C; Zhao P; Megati S; Yurgelonis I; Lee PK; Matsuka YV; Severina E; Deatly A; Sidhu M; Jansen KU; Minton NP; Anderson AS
Microbiology (Reading); 2013 Jul; 159(Pt 7):1254-1266. PubMed ID: 23629868
[TBL] [Abstract][Full Text] [Related]
27. Masking autoprocessing of Clostridium difficile toxin A by the C-terminus combined repetitive oligo peptides.
Zhang Y; Hamza T; Gao S; Feng H
Biochem Biophys Res Commun; 2015 Apr; 459(2):259-263. PubMed ID: 25725153
[TBL] [Abstract][Full Text] [Related]
28. Structural determinants of Clostridium difficile toxin A glucosyltransferase activity.
Pruitt RN; Chumbler NM; Rutherford SA; Farrow MA; Friedman DB; Spiller B; Lacy DB
J Biol Chem; 2012 Mar; 287(11):8013-20. PubMed ID: 22267739
[TBL] [Abstract][Full Text] [Related]
29. An optimized, synthetic DNA vaccine encoding the toxin A and toxin B receptor binding domains of Clostridium difficile induces protective antibody responses in vivo.
Baliban SM; Michael A; Shammassian B; Mudakha S; Khan AS; Cocklin S; Zentner I; Latimer BP; Bouillaut L; Hunter M; Marx P; Sardesai NY; Welles SL; Jacobson JM; Weiner DB; Kutzler MA
Infect Immun; 2014 Oct; 82(10):4080-91. PubMed ID: 25024365
[TBL] [Abstract][Full Text] [Related]
30. Human α-Defensin-6 Neutralizes
Barthold L; Heber S; Schmidt CQ; Gradl M; Weidinger G; Barth H; Fischer S
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35562899
[TBL] [Abstract][Full Text] [Related]
31. Substrate specificity of clostridial glucosylating toxins and their function on colonocytes analyzed by proteomics techniques.
Zeiser J; Gerhard R; Just I; Pich A
J Proteome Res; 2013 Apr; 12(4):1604-18. PubMed ID: 23387933
[TBL] [Abstract][Full Text] [Related]
32. Toward a structural understanding of Clostridium difficile toxins A and B.
Pruitt RN; Lacy DB
Front Cell Infect Microbiol; 2012; 2():28. PubMed ID: 22919620
[TBL] [Abstract][Full Text] [Related]
33. Mechanism of action and epitopes of Clostridium difficile toxin B-neutralizing antibody bezlotoxumab revealed by X-ray crystallography.
Orth P; Xiao L; Hernandez LD; Reichert P; Sheth PR; Beaumont M; Yang X; Murgolo N; Ermakov G; DiNunzio E; Racine F; Karczewski J; Secore S; Ingram RN; Mayhood T; Strickland C; Therien AG
J Biol Chem; 2014 Jun; 289(26):18008-21. PubMed ID: 24821719
[TBL] [Abstract][Full Text] [Related]
34. Glucosylation Drives the Innate Inflammatory Response to Clostridium difficile Toxin A.
Cowardin CA; Jackman BM; Noor Z; Burgess SL; Feig AL; Petri WA
Infect Immun; 2016 Aug; 84(8):2317-2323. PubMed ID: 27271747
[TBL] [Abstract][Full Text] [Related]
35. Domperidone Protects Cells from Intoxication with
Braune-Yan M; Jia J; Wahba M; Schmid J; Papatheodorou P; Barth H; Ernst K
Toxins (Basel); 2023 Jun; 15(6):. PubMed ID: 37368685
[No Abstract] [Full Text] [Related]
36. Clostridium difficile Toxin Biology.
Aktories K; Schwan C; Jank T
Annu Rev Microbiol; 2017 Sep; 71():281-307. PubMed ID: 28657883
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.
Yang Z; Ramsey J; Hamza T; Zhang Y; Li S; Yfantis HG; Lee D; Hernandez LD; Seghezzi W; Furneisen JM; Davis NM; Therien AG; Feng H
Infect Immun; 2015 Feb; 83(2):822-31. PubMed ID: 25486992
[TBL] [Abstract][Full Text] [Related]
38.
McKee HK; Kajiwara C; Yamaguchi T; Ishii Y; Shimizu N; Ohara A; Tateda K
J Med Microbiol; 2021 Apr; 70(4):. PubMed ID: 33830910
[No Abstract] [Full Text] [Related]
39. The roles of toxin A and toxin B in Clostridium difficile infection: insights from the gnotobiotic piglet model.
Steele J; Parry N; Tzipori S
Gut Microbes; 2014; 5(1):53-7. PubMed ID: 24394234
[TBL] [Abstract][Full Text] [Related]
40. Human monoclonal antibodies against Clostridium difficile toxins A and B inhibit inflammatory and histologic responses to the toxins in human colon and peripheral blood monocytes.
Koon HW; Shih DQ; Hing TC; Yoo JH; Ho S; Chen X; Kelly CP; Targan SR; Pothoulakis C
Antimicrob Agents Chemother; 2013 Jul; 57(7):3214-23. PubMed ID: 23629713
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
